Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Harvard Business School
Moodys
Johnson and Johnson
Dow

Last Updated: October 22, 2019

DrugPatentWatch Database Preview

EXELON Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Exelon, and what generic alternatives are available?

Exelon is a drug marketed by Novartis and is included in three NDAs. There are two patents protecting this drug and four Paragraph IV challenges.

This drug has thirty-seven patent family members in twenty-seven countries.

The generic ingredient in EXELON is rivastigmine. There are thirty-two drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the rivastigmine profile page.

Drug patent expirations by year for EXELON
Drug Prices for EXELON

See drug prices for EXELON

Recent Clinical Trials for EXELON

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
SocraTec R&D GmbHPhase 1
SocraMetrics GmbHPhase 1
University of PennsylvaniaPhase 4

See all EXELON clinical trials

Recent Litigation for EXELON

Identify potential future generic entrants

District Court Litigation
Case NameDate
NOVARTIS PHARMACEUTICALS CORPORATION v. DR. REDDYS LABORATORIES, LTD.2015-11-06
Novartis Pharmaceuticals Corporation v. Amneal Pharmaceuticals LLC2015-11-05
Novartis Pharmaceuticals Corporation v. Dr. Reddy's Laboratories, Ltd.2015-11-05

See all EXELON litigation

PTAB Litigation
PetitionerDate
Mylan Pharmaceuticals Inc.2014-11-13
Noven Pharmaceuticals, Inc.2014-04-02

See all EXELON litigation

Pharmacology for EXELON
Synonyms for EXELON
(R)-Rivastigmine (Rivastigmine EP Impurity D)
(S)-1-(3-((ethyl(methyl)carbamoyl)oxy)phenyl)-N,N-dimethylethanamine
(S)-3-(1-(dimethylamino)ethyl)phenyl ethyl(methyl)carbamate
(S)-3-(1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
(S)-3-[1-(dimethylamino)ethyl]phenyl N-ethyl-N-methylcarbamate
[3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methyl-carbamate
[3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methylcarbamate
[3-[(1S)-1-dimethylaminoethyl]phenyl] N-ethyl-N-methylcarbamate
101R548
123441-03-2
2,3-dihydroxybutanedioic acid; 3-[(1S)-1-(dimethylamino)ethyl]phenyl N-ethyl-N-methylcarbamate
3-((1S)-1-(Dimethylamino)ethyl)phenyl N-ethyl-N-methylcarbamate
3-((1S)-1-(Dimethylamino)ethyl)phenyl N-ethyl-N-methylcarbamate; Ethylmethylcarbamic acid 3-((1S)-1-(dimethylamino)ethyl)phenyl ester
3-((1S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
3-((1S)-1-(Dimethylamino)ethyl)phenyl N-ethyl N-methyl carbamate
3-[(1S)-1-(dimethylamino)ethyl]phenyl ethyl(methyl)carbamate
3-[(1S)-1-(dimethylamino)ethyl]phenyl N-ethyl-N-methylcarbamate
AB01275472_02
AB01275472_03
AB01275472-01
AB1004572
ABP001082
AC-8250
AC1L2U92
AJ-08211
AK161672
AKOS015896334
AN-1074
API0008913
BC225687
BDBM10620
BDBM11682
BIDD:GT0316
C-23825
C11766
Carbamic acid, ethylmethyl-, 3-((1S)-1-(dimethylamino)ethyl)phenyl ester
Carbamic acid, ethylmethyl-, 3-(1-(dimethylamino)ethyl)phenyl ester, (S)-
Carbamic acid, N-ethyl-N-methyl-, 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester
CC-34273
CCG-221197
CHEBI:8874
CHEMBL636
CS-0946
D03822
DB00989
DTXSID7023564
EBD46209
ENA 713 free base
ENA-713
Ethyl-methyl-carbamic acid 3-((R)-1-dimethylamino-ethyl)-phenyl ester
Ethyl-methyl-carbamic acid 3-((S)-1-dimethylamino-ethyl)-phenyl ester
Ethyl-methyl-carbamic acid 3-(1-dimethylamino-ethyl)-phenyl ester
Ethylmethylcarbamic acid 3-((1S)-1-(dimethylamino)ethyl)phenyl ester
Exelon Patch
F10108
FT-0651952
GTPL6602
HMS2089H18
HMS3715P15
HY-17368
I06-2037
KS-00000H18
LS-172571
m-((S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
MLS003876822
MolPort-003-666-662
NCGC00167531-03
Nimvastid
PKI06M3IW0
Prometax (TN)
rivastigmine
Rivastigmine (JAN/USAN/INN)
Rivastigmine [USAN:INN:BAN:JAN]
Rivastigmine [USAN:INN]
Rivastigmine Teva
Rivastigmine Transdermal System
Rivastigmine.tartrate
RL06150
S4687
SCHEMBL2764
SDZ 212-713
SDZ-212-713
SDZ-ENA-713
SMR002203623
SR-05000001475
SR-05000001475-1
SR-05000001475-2
ST24049123
UNII-PKI06M3IW0
W-200966
W-5183
XSVMFMHYUFZWBK-NSHDSACASA-N
Y9059
ZINC4413

US Patents and Regulatory Information for EXELON

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis EXELON rivastigmine tartrate CAPSULE;ORAL 020823-003 Apr 21, 2000 DISCN Yes No   Start Trial   Start Trial   Start Trial
Novartis EXELON rivastigmine FILM, EXTENDED RELEASE;TRANSDERMAL 022083-002 Jul 6, 2007 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Novartis EXELON rivastigmine tartrate CAPSULE;ORAL 020823-006 Apr 21, 2000 DISCN Yes No   Start Trial   Start Trial   Start Trial
Novartis EXELON rivastigmine FILM, EXTENDED RELEASE;TRANSDERMAL 022083-002 Jul 6, 2007 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for EXELON

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis EXELON rivastigmine FILM, EXTENDED RELEASE;TRANSDERMAL 022083-002 Jul 6, 2007   Start Trial   Start Trial
Novartis EXELON rivastigmine FILM, EXTENDED RELEASE;TRANSDERMAL 022083-002 Jul 6, 2007   Start Trial   Start Trial
Novartis EXELON rivastigmine FILM, EXTENDED RELEASE;TRANSDERMAL 022083-005 Aug 31, 2012   Start Trial   Start Trial
Novartis EXELON rivastigmine tartrate CAPSULE;ORAL 020823-003 Apr 21, 2000   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for EXELON
Drugname Dosage Strength RLD Date
➤ Subscribe Transdermal System Extended-release 13.3 mg/24 hr ➤ Subscribe   Start Trial
➤ Subscribe Transdermal System Extended-release 4.6 mg/24 hr and 9.5 mg/24 hr ➤ Subscribe   Start Trial
➤ Subscribe Oral Solution 2 mg/mL ➤ Subscribe   Start Trial
➤ Subscribe Capsules 1.5 mg, 3 mg, 4.5 mg and 6 mg ➤ Subscribe   Start Trial

Supplementary Protection Certificates for EXELON

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0193926 C980031 Netherlands   Start Trial PRODUCT NAME: RIVASTIGMINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER RIVASTIGMINE WATERSTOFTAR- TRAAT; REGISTRATION NO/DATE: EU/1/98/066/001 - EU/1/98/066/012 19980512
0193926 98C0038 Belgium   Start Trial PRODUCT NAME: RIVASTIGMINE; NAT. REGISTRATION NO/DATE: EU/1/98/066/001 19980512; FIRST REGISTRATION: CH 54275 01 19970731
0193926 SPC/GB98/041 United Kingdom   Start Trial PRODUCT NAME: RIVASTIGMINE, AS FREE BASE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: CH 5427501 19970731; CH 5427502 19970731; CH 5427503 19970731; CH 5427504 19970731; CH 5427505 19970731; CH 5427506 19970731; UK EU/1/98/066/001 19980512; UK EU/1/98/066/002 19980512; UK EU/1/98/066/003 19980512; UK EU/1/98/066/004 19980512; UK EU/1/98/066/005 19980512; UK EU/1/98/066/006 19980512; UK EU/1/98/092/023 19980512; UK EU/1/98/092/024 19980512; UK EU/1/98/092/025 19980512; UK EU/1/98/092/026 19980512; UK EU/1/98/066/025 19980512; UK EU/1/98/066/026 19980512; UK EU/1/98/092/019 19980512; UK EU/1/98/092/020 19980512; UK EU/1/98/092/021 19980512; UK EU/1/98/092/022 19980512; UK EU/1/98/0
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Harvard Business School
Merck
Dow
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.